- Home
- BRN vs CMMB Comparison
BRN vs CMMB Comparison
Compare BRN & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRN
- CMMB
- Stock Information
- Founded
- BRN 1956
- CMMB 2004
- Country
- BRN United States
- CMMB Israel
- Employees
- BRN N/A
- CMMB N/A
- Industry
- BRN Oil & Gas Production
- CMMB Biotechnology: Pharmaceutical Preparations
- Sector
- BRN Energy
- CMMB Health Care
- Exchange
- BRN Nasdaq
- CMMB Nasdaq
- Market Cap
- BRN 12.2M
- CMMB 13.7M
- IPO Year
- BRN N/A
- CMMB N/A
- Fundamental
- Price
- BRN $1.20
- CMMB $2.58
- Analyst Decision
- BRN
- CMMB Strong Buy
- Analyst Count
- BRN 0
- CMMB 2
- Target Price
- BRN N/A
- CMMB $26.50
- AVG Volume (30 Days)
- BRN 99.9K
- CMMB 151.5K
- Earning Date
- BRN 12-15-2025
- CMMB 11-12-2025
- Dividend Yield
- BRN N/A
- CMMB N/A
- EPS Growth
- BRN N/A
- CMMB N/A
- EPS
- BRN N/A
- CMMB N/A
- Revenue
- BRN $18,073,000.00
- CMMB N/A
- Revenue This Year
- BRN N/A
- CMMB N/A
- Revenue Next Year
- BRN N/A
- CMMB N/A
- P/E Ratio
- BRN N/A
- CMMB N/A
- Revenue Growth
- BRN N/A
- CMMB N/A
- 52 Week Low
- BRN $1.08
- CMMB $2.39
- 52 Week High
- BRN $2.28
- CMMB $9.84
- Technical
- Relative Strength Index (RSI)
- BRN 45.13
- CMMB 38.12
- Support Level
- BRN $1.21
- CMMB $2.95
- Resistance Level
- BRN $1.34
- CMMB $2.80
- Average True Range (ATR)
- BRN 0.09
- CMMB 0.26
- MACD
- BRN -0.00
- CMMB -0.09
- Stochastic Oscillator
- BRN 44.23
- CMMB 2.30
About BRN Barnwell Industries Inc.
Barnwell Industries Inc is an oil and gas firm. Its areas of operations include acquiring, developing, producing, and selling oil and natural gas. The company acquires and develops crude oil and natural gas assets. The company's operating segment includes Oil and natural gas, Contract drilling, Land investment, and Others. It generates maximum revenue from the Oil and natural gas segment. It operates in two geographical segments the United States, which generates a majority of revenue, and Canada.
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.